Navigation Links
Ikaria Strengthens Executive Leadership Team
Date:10/2/2008

- Head of Engineering and Operations Appointed -

CLINTON, N.J., Oct. 2 /PRNewswire/ -- Ikaria Holdings, Inc. today announced the appointment of Michael Kennedy as Senior Vice President, Engineering and Operations. In this role, Kennedy will be responsible for drug-device technology strategy and development.

"Michael's extensive experience will help Ikaria strengthen its leadership in critical care as we continue to advance our pharmaceutical pipeline through a number of strategies including our strong commitment to drug-device development," said Daniel Tasse', President and CEO of Ikaria. "I am pleased to welcome Michael, who will complete our executive leadership team."

Most recently, Kennedy served as Vice President, Technology Platform Development in the Pharmaceutical and Technology Division of Baxter International Inc., where he led drug-device technology strategy and development across the organization's portfolio. Previously he led the global development of Baxter's industry-leading dialysis and transfusion therapy innovations. Kennedy's executive experience also includes senior positions at General Electric, Hollister Inc. and Comdisco Healthcare Group.

About Ikaria Holdings, Inc.

Ikaria Holdings, Inc. is a fully integrated biotherapeutics company focused on the development and commercialization of innovative pharmaceuticals, biologic messengers and drug-device combinations for hospitalized, critically ill patients. The company's lead product, INOmax(R) (nitric oxide) for inhalation, is the only FDA-approved drug for the treatment of hypoxic respiratory failure in term and near-term newborns, and also is marketed in Canada, Europe, Australia and Latin America. INOmax recently was approved for marketing in Japan. Ikaria is engaged in new and ongoing clinical development of INOmax, Covox(R) (carbon monoxide) for inhalation and hydrogen sulfide. Ikaria is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI, and a manufacturing facility in Port Allen, LA. For more information, please visit http://www.ikaria.com.

CONTACT:

Samina Bari

Ikaria

(908) 238-6372

samina.bari@ikaria.com


'/>"/>
SOURCE Ikaria Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Ikaria(R) Strengthens Commercial Operations and Human Resources Leadership
2. Ikaria Introduces Dr. Michael Cooreman as Vice President of Translational Medicine
3. Lota Zoth Elected to Ikaria Board and Named Audit Committee Chair
4. Ikaria Appoints Daniel Tasse as President and Chief Executive Officer
5. Ikaria to Present at 26th Annual JPMorgan Healthcare Conference
6. Ikaria Founding Scientist Named 2007 MacArthur Fellow
7. New Study Shows Promise for Hydrogen Sulfide in Reducing Heart-Attack Damage, Ikaria Announces
8. Algenol Biofuels Further Strengthens Team With Key Appointments
9. InNexus Biotechnology Strengthens Patent Team With New Leadership
10. InVitria Further Strengthens Sales Team with Promotion of Brandy Sargent to Account Manager - Western United States
11. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... Brain ... to begin marketing the SPEAC® System, the Brain Sentinel® Seizure Monitoring and Alerting ... in healthcare facilities during periods of rest. A lightweight, non-invasive monitor is placed ...
(Date:2/23/2017)... ... 2017 , ... Today, researchers can fast-track sample collection and ... other biomarkers or SNPs of interest) using one, easy-to-collect saliva sample. With the ... between insulin and other relevant biomarkers can be extensively studied through a non-invasive ...
(Date:2/23/2017)... DIEGO , Feb. 23, 2017 ... research tools, announced the acquisition of GenWay Biotech ... a comprehensive service and product offering for both ... acquisition will facilitate growth and enhance capabilities for ... antibodies, and ELISA assays will nicely complement ASB,s ...
(Date:2/22/2017)... , Feb. 22, 2017  Aratana Therapeutics, Inc. (NASDAQ: PETX), ... commercialization of innovative biopharmaceutical products for companion animals, will host ... 8:30 a.m. ET to discuss financial results from the fourth ... Interested participants and investors may access the audio ... ...
Breaking Biology Technology:
(Date:2/8/2017)... , Feb. 8, 2017 About Voice ... voice to match it against a stored voiceprint ... as pitch, cadence, and tone are compared to ... minimal hardware installation, as most PCs already have ... different transactions. Voice recognition biometrics are most likely ...
(Date:2/8/2017)... 2017 Report Highlights ... The global synthetic-biology market reached nearly ... 2021, growing at a compound annual growth rate (CAGR) of ... the global markets for synthetic biology. - Analyses of global ... projections of compound annual growth rates (CAGRs) through 2021. - ...
(Date:2/8/2017)... -- Report Highlights The global biosurgery market ... in 2016 at a compound annual growth rate (CAGR) ... - An overview of the global market for biosurgery. ... 2015 and 2016, and projections of compound annual growth ... on the basis of product type, source, application, and ...
Breaking Biology News(10 mins):